Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Get Free Report) saw a large decline in short interest in July. As of July 31st, there was short interest totaling 1,385 shares, a decline of 49.3% from the July 15th total of 2,733 shares. Based on an average daily trading volume, of 790 shares, the short-interest ratio is currently 1.8 days. Currently, 0.0% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

• Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy

Several research firms have recently weighed in on MOLN. Weiss Ratings restated a "sell (d-)" rating on shares of Molecular Partners in a research report on Wednesday, July 8th. HC Wainwright reissued a "buy" rating on shares of Molecular Partners in a research note on Monday, July 6th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $8.38.

Check Out Our Latest Report on Molecular Partners

Molecular Partners Trading Down 2.5%

NASDAQ MOLN traded down $0.10 on Friday, reaching $4.11. 1,036 shares of the company were exchanged, compared to its average volume of 897. The business's fifty day moving average price is $3.99 and its 200 day moving average price is $4.23. The stock has a market capitalization of $165.74 million, a P/E ratio of -2.12 and a beta of 1.08. Molecular Partners has a fifty-two week low of $3.47 and a fifty-two week high of $5.36.

Institutional Investors Weigh In On Molecular Partners

A hedge fund recently bought a new position in Molecular Partners stock. SmartHarvest Portfolios LLC acquired a new stake in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 12,311 shares of the company's stock, valued at approximately $54,000. 26.55% of the stock is currently owned by hedge funds and other institutional investors.

About Molecular Partners

(Get Free Report)

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company's technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company's development pipeline spans infectious diseases, ophthalmology and oncology.

Featured Stories

• Five stocks we like better than Molecular Partners
• The Metals Company’s Big Bet Now Comes Down to a License
• OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
• Meta and Tesla Are Rebounding From Oversold Levels—Now What?
• AMG’s Alternatives Boom Powers Record Growth

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Molecular Partners Right Now?

Before you consider Molecular Partners, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Molecular Partners wasn't on the list.

While Molecular Partners currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here